US1265208A
(en)
|
1915-09-07 |
1918-05-07 |
Edward C Kahn |
Liquid-fuel burner.
|
JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
EP0548276A4
(en)
*
|
1990-09-13 |
1993-12-29 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
US6162896A
(en)
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
AU654724B2
(en)
|
1991-05-10 |
1994-11-17 |
Salk Institute For Biological Studies, The |
Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
DK0592562T3
(da)
|
1991-06-25 |
1999-08-30 |
Genetics Inst |
BMP-9-præparater
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
EP0679163A4
(en)
|
1993-01-12 |
1997-07-16 |
Univ Johns Hopkins Med |
FACTOR-3 OF GROWTH AND DIFFERENTIATION.
|
US5354934A
(en)
|
1993-02-04 |
1994-10-11 |
Amgen Inc. |
Pulmonary administration of erythropoietin
|
AU677849B2
(en)
|
1993-05-12 |
1997-05-08 |
Genetics Institute, Llc |
BMP-10 compositions
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
US5831050A
(en)
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
ATE355369T1
(de)
|
1993-10-14 |
2006-03-15 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
ATE352638T1
(de)
|
1995-04-11 |
2007-02-15 |
Gen Hospital Corp |
REVERSE ßTWO-HYBRIDß-SYSTEME
|
EP0771873A3
(en)
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
US6372480B1
(en)
*
|
1996-04-19 |
2002-04-16 |
Mycogen Corporation |
Pesticidal proteins
|
AU721196B2
(en)
|
1996-10-25 |
2000-06-29 |
G.D. Searle & Co. |
Circularly permuted erythropoietin receptor agonists
|
US6017534A
(en)
*
|
1996-11-20 |
2000-01-25 |
Ecogen, Inc. |
Hybrid Bacillus thuringiensis δ-endotoxins with novel broad-spectrum insecticidal activity
|
US6605699B1
(en)
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
US6034062A
(en)
|
1997-03-13 |
2000-03-07 |
Genetics Institute, Inc. |
Bone morphogenetic protein (BMP)-9 compositions and their uses
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
JP2001513982A
(ja)
|
1997-08-29 |
2001-09-11 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
フォリスタチン−3
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
RU2221809C2
(ru)
|
1997-10-03 |
2004-01-20 |
Тугаи Сейяку Кабусики Кайся |
Способ получения природного гуманизированного антитела
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
BR9913857A
(pt)
|
1998-09-17 |
2001-06-12 |
Lilly Co Eli |
Formulações de proteìna
|
AU5502799A
(en)
|
1998-09-22 |
2000-04-10 |
Long Yu |
New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
EP1131084A4
(en)
|
1998-10-30 |
2001-12-19 |
Genetics Inst |
INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL)
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
NZ513642A
(en)
|
1999-01-21 |
2004-02-27 |
Metamorphix Inc |
Growth differentiation factor inhibitors and uses therefor
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
CA2365449A1
(en)
|
1999-04-19 |
2000-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibitor of the growth of androgen-independent tumor
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
WO2001036001A2
(en)
|
1999-11-12 |
2001-05-25 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
NZ519546A
(en)
|
1999-12-15 |
2005-07-29 |
Res Dev Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
US20030224501A1
(en)
|
2000-03-17 |
2003-12-04 |
Young Paul E. |
Bone morphogenic protein polynucleotides, polypeptides, and antibodies
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
WO2001087329A1
(en)
|
2000-05-15 |
2001-11-22 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivate
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
WO2002008277A2
(en)
|
2000-07-19 |
2002-01-31 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
US7048949B2
(en)
|
2000-11-20 |
2006-05-23 |
The Board Of Trustees Of The University Of Illinois |
Membrane scaffold proteins
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
EP1370287A2
(en)
|
2000-12-01 |
2003-12-17 |
Wyeth |
Method and composition for modulating bone growth
|
TWI329129B
(en)
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
WO2002074340A1
(fr)
|
2001-03-16 |
2002-09-26 |
Takeda Chemical Industries, Ltd. |
Procede de fabrication d'une preparation a liberation continue
|
SI1436003T1
(sl)
|
2001-05-24 |
2010-02-26 |
Zymogenetics Inc |
TACI-imunoglobulinski fuzijski proteini
|
JP2005508141A
(ja)
|
2001-05-25 |
2005-03-31 |
セローノ ジェネティクス インスティテュート ソシエテ アニニム |
ヒトcDNAおよびタンパク質、ならびにそれらの使用
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
US7396642B2
(en)
|
2001-07-17 |
2008-07-08 |
Teijin Limited |
Methods of screening for a compound that enhances thermogenesis
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
EP2324834B1
(en)
|
2001-12-06 |
2019-05-08 |
Fibrogen, Inc. |
Methods of Increasing Endogenous Erythropoietin (EPO)
|
US20060234918A1
(en)
|
2001-12-19 |
2006-10-19 |
Voyager Pharmaceutical Corporation |
Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
EP1573002A4
(en)
|
2002-02-11 |
2008-07-16 |
Genentech Inc |
ANTIBODY VARIANTS WITH ACCELERATED ANTIGEN ASSOCIATED SPEEDS
|
IL163525A0
(en)
|
2002-02-21 |
2005-12-18 |
Wyeth Corp |
A follistatin domain containing protein
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
AU2003232485A1
(en)
|
2002-04-18 |
2003-10-27 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
BR0313729A
(pt)
|
2002-08-16 |
2005-06-21 |
Wyeth Corp |
Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo
|
AU2003228509B2
(en)
|
2002-10-15 |
2008-06-26 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
EA009939B1
(ru)
|
2003-02-07 |
2008-04-28 |
Прометик Байосайенсиз, Инк. |
Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза
|
US20070155661A1
(en)
|
2003-02-14 |
2007-07-05 |
The Board Of Trustees Of The Leland Standord Junior University |
Methods and compositions for modulating the development of stem cells
|
GB0304424D0
(en)
|
2003-02-26 |
2003-04-02 |
Glaxosmithkline Biolog Sa |
Novel compounds
|
US20040197828A1
(en)
|
2003-03-26 |
2004-10-07 |
Gaddy Dana P. |
Method for diagnosis and treatment of bone turnover
|
US20070184052A1
(en)
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
WO2004108157A2
(en)
|
2003-06-02 |
2004-12-16 |
Wyeth |
Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
WO2005070967A2
(en)
|
2004-01-22 |
2005-08-04 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
CA2561317A1
(en)
|
2004-03-26 |
2005-10-13 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
US7459527B2
(en)
|
2004-03-31 |
2008-12-02 |
Xencor, Inc. |
BMP-7 variants with improved properties
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
AU2005258286A1
(en)
|
2004-06-24 |
2006-01-05 |
Acceleron Pharma Inc. |
GDF3 propeptides and related methods
|
WO2006012527A1
(en)
|
2004-07-23 |
2006-02-02 |
Endocyte, Inc. |
Bivalent linkers and conjugates thereof
|
ES2561048T3
(es)
*
|
2004-07-23 |
2016-02-24 |
Acceleron Pharma Inc. |
Polipéptidos del receptor ActRII
|
EP1794191B1
(en)
|
2004-08-05 |
2016-05-18 |
The Regents of The University of California |
Molecules with effects on cellular development and function
|
US7095608B2
(en)
|
2004-08-12 |
2006-08-22 |
Audiovox Corporation |
Video display mounting system and method
|
BRPI0514253A
(pt)
|
2004-08-12 |
2008-06-03 |
Wyeth Corp |
terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
BRPI0518728A2
(pt)
|
2004-12-09 |
2008-12-02 |
Univ Pittsburgh |
vacinas para a resposta rÁpida À pandemia de gripe aviÁria
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
ES2547866T3
(es)
|
2005-02-16 |
2015-10-09 |
The General Hospital Corporation |
Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
|
JPWO2006115274A1
(ja)
|
2005-04-26 |
2008-12-18 |
味の素株式会社 |
骨髄赤血球前駆細胞分化促進剤
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
US20070238658A1
(en)
|
2005-09-28 |
2007-10-11 |
Levin Steven D |
IL-17A and IL-17F Antagonists and Methods of Using the Same
|
JP5361386B2
(ja)
|
2005-10-07 |
2013-12-04 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
マトリックスメタロプロテイナーゼ11ワクチン
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
KR20160137665A
(ko)
|
2005-11-23 |
2016-11-30 |
악셀레론 파마 인코포레이티드 |
액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
EP1968621A2
(en)
|
2005-12-06 |
2008-09-17 |
Amgen Inc. |
Uses of myostatin antagonists
|
WO2007071023A1
(en)
|
2005-12-20 |
2007-06-28 |
Merck Frosst Canada Ltd. |
Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
MX2008008340A
(es)
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
|
EP1973909A2
(en)
|
2005-12-22 |
2008-10-01 |
Biogen Idec MA Inc. |
Transforming growth factor modulators
|
EP2016423B1
(en)
|
2006-01-20 |
2011-07-13 |
Beckman Coulter, Inc. |
Methods of detection of iron deficiency
|
JP2009531280A
(ja)
|
2006-01-25 |
2009-09-03 |
ウェルスタット セラピューティクス コーポレイション |
代謝障害を処置するための化合物
|
KR20080098615A
(ko)
|
2006-02-28 |
2008-11-11 |
웰스태트 테러퓨틱스 코포레이션 |
물질대사 장애의 치료용 화합물
|
CA2650131A1
(en)
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
AU2007249827A1
(en)
|
2006-05-09 |
2007-11-22 |
Colorado State University Research Foundation |
Methods for treating blood disorders
|
NZ574331A
(en)
|
2006-07-21 |
2011-01-28 |
Lyne Lab |
Liquid compositions of calcium acetate
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
WO2008073292A2
(en)
|
2006-12-08 |
2008-06-19 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
|
EP2103628A4
(en)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
NZ707292A
(en)
|
2006-12-18 |
2017-06-30 |
Acceleron Pharma Inc |
Activin-actrii antagonists and uses for increasing red blood cell levels
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
AU2008211007B2
(en)
|
2007-02-01 |
2013-09-19 |
Acceleron Pharma Inc. |
Activin-ActRIIa antagonists and uses for treating or preventing breast cancer
|
TW202021980A
(zh)
|
2007-02-02 |
2020-06-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
CA3039330C
(en)
|
2007-02-09 |
2021-11-09 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for promoting bone growth in cancer patients
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
CA2685306A1
(en)
|
2007-06-01 |
2008-12-11 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
RS55735B1
(sr)
|
2007-08-03 |
2017-07-31 |
Summit (Oxford) Ltd |
Kombinacije lekova za lečenje dišenove mišićne distrofije
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
US20100279409A1
(en)
|
2007-09-13 |
2010-11-04 |
Neil Robson |
Method for modifying celluar immune resonse by modulating activin activity
|
CN107412734A
(zh)
|
2007-09-18 |
2017-12-01 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
WO2009070243A2
(en)
|
2007-11-21 |
2009-06-04 |
Amgen Inc. |
Wise binding agents and epitopes
|
WO2009114180A1
(en)
|
2008-03-13 |
2009-09-17 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
EP2283119B1
(en)
|
2008-05-06 |
2015-01-07 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
EP3363453A1
(en)
|
2008-06-26 |
2018-08-22 |
Acceleron Pharma Inc. |
Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
|
EP3620795A1
(en)
|
2008-06-26 |
2020-03-11 |
Acceleron Pharma Inc. |
Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
JP5922928B2
(ja)
|
2008-08-14 |
2016-05-24 |
アクセルロン ファーマ, インコーポレイテッド |
赤血球レベルを高めるためのgdfトラップの使用
|
WO2010059861A1
(en)
|
2008-11-20 |
2010-05-27 |
University Of Southern California |
Compositions and methods to modulate hair growth
|
PE20120206A1
(es)
|
2008-11-26 |
2012-03-09 |
Amgen Inc |
Variantes de polipeptidos receptores de activina iib
|
EP2387412A4
(en)
|
2009-01-13 |
2013-04-03 |
Acceleron Pharma Inc |
METHODS FOR INCREASING ADIPONECTIN
|
US8110355B2
(en)
|
2009-02-20 |
2012-02-07 |
GenRemedy, LLC |
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
|
JP5766179B2
(ja)
|
2009-04-27 |
2015-08-19 |
ノバルティス アーゲー |
筋肉増殖を増加させるための組成物および方法
|
EP2440576A4
(en)
|
2009-06-08 |
2013-11-20 |
Acceleron Pharma Inc |
PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
|
AU2010263182B2
(en)
|
2009-06-12 |
2016-05-12 |
Acceleron Pharma Inc. |
Truncated ActRIIB-Fc fusion proteins
|
MX2012001916A
(es)
|
2009-08-13 |
2012-05-22 |
Acceleron Pharma Inc |
Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.
|
AU2010292203A1
(en)
|
2009-09-09 |
2012-04-12 |
Acceleron Pharma Inc. |
ActRIIb antagonists and dosing and uses thereof
|
US20110129469A1
(en)
|
2009-11-03 |
2011-06-02 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
CA2781152A1
(en)
|
2009-11-17 |
2011-05-26 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
US9595813B2
(en)
|
2011-01-24 |
2017-03-14 |
Soraa Laser Diode, Inc. |
Laser package having multiple emitters configured on a substrate member
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
ES2692519T3
(es)
|
2011-07-01 |
2018-12-04 |
Novartis Ag |
Método para tratar trastornos metabólicos
|
CN107837390A
(zh)
|
2011-10-17 |
2018-03-27 |
阿塞勒隆制药公司 |
用于治疗无效性红细胞生成的方法和组合物
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
US8765385B2
(en)
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
US20140303068A1
(en)
|
2011-10-28 |
2014-10-09 |
Paranta Biosciences Limited |
Method of treating mucus hypersecretion
|
SG11201403367YA
(en)
|
2011-12-19 |
2014-07-30 |
Amgen Inc |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
EP3521310A1
(en)
|
2012-06-14 |
2019-08-07 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
Use of blocking agents of bone morphogenic protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
|
KR102143476B1
(ko)
|
2012-07-02 |
2020-08-12 |
쿄와 기린 가부시키가이샤 |
항bmp9 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제
|
EP2912462B1
(en)
|
2012-10-24 |
2019-08-07 |
Celgene Corporation |
Biomarker for use in treating anemia
|
CN112933223A
(zh)
|
2012-10-24 |
2021-06-11 |
细胞基因公司 |
用于治疗贫血的方法
|
WO2014064292A1
(en)
|
2012-10-26 |
2014-05-01 |
Universite Pierre Et Marie Curie (Paris 6) |
A method for preventing or treating atrial fibrillation
|
ES2884095T3
(es)
|
2012-11-02 |
2021-12-10 |
Celgene Corp |
Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
|
KR20150083117A
(ko)
|
2012-11-08 |
2015-07-16 |
클리어사이드 바이오메디컬, 인코포레이드 |
인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
|
US20150328249A1
(en)
|
2012-12-11 |
2015-11-19 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
WO2014152940A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
TW201920262A
(zh)
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素a之抗體及其用途
|
CN105960414A
(zh)
|
2013-08-14 |
2016-09-21 |
诺华股份有限公司 |
治疗散发性包涵体肌炎的方法
|
EP3084000A4
(en)
|
2013-12-16 |
2017-09-20 |
Paranta Biosciences Limited |
Method of diagnosis and treatment
|
EP3094751A4
(en)
|
2014-01-14 |
2017-06-07 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
US20170248609A1
(en)
|
2014-01-27 |
2017-08-31 |
Novartis Ag |
Biomarkers predictive of muscle atrophy, method and use
|
JP6601687B2
(ja)
|
2014-03-31 |
2019-11-06 |
大日本住友製薬株式会社 |
進行性骨化性線維異形成症の予防剤及び治療剤
|
ES2845650T3
(es)
|
2014-04-18 |
2021-07-27 |
Acceleron Pharma Inc |
Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
BR112016029211A2
(pt)
|
2014-06-13 |
2018-01-30 |
Amgen Inc |
composição, método para inibir um crescimento tumoral sólido em um indivíduo, método para produzir uma proteína, método para inibir, reduzir ou tratar de caquexia em um indivíduo, método para tratar obesidade ou uma doença associada à obesidade e kit
|
BR122023023170A2
(pt)
|
2014-06-13 |
2024-02-20 |
Acceleron Pharma Inc. |
Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
|
CN107847562A
(zh)
|
2015-05-13 |
2018-03-27 |
细胞基因公司 |
使用 ACTRII 配体陷阱治疗 β‑地中海贫血
|